Volatility is the new certainty after governments and investors ‘shoot first and ask questions later’

Covid-19, in its new mutated version, came back to again remind us where the control lies during this pandemic. News of the ominously named Omicron variant saw, as one trader put it, governments and investors “shoot first and ask questions later”.

The oil price dropped by $10 to $72 a barrel as countries around the world withdrew travel access to southern Africa forthwith and then Japan and China imposed broader restrictions in line with their zero-Covid strategies. It remains close to that in anticipation of lower demand.

Developed stock markets lost between 2.5% and 3.5% on concerns the variant would stall economies again. South Africa, initially viewed as the epicentre of Omicron, and penalised as such, saw the rand push above R16 to the dollar before regaining some ground as it became clear that there were cases of the variant around the world.

As the dust has settled, analysts are still grappling with what this new variant could mean for the outlook for financial markets and the global economy. Anecdotal evidence suggests that it may not be as vicious as the Delta variant, with initial indications that infected people experience only mild symptoms. But most investment houses have been careful to emphasise the downside risks that have been introduced; setting out a base-, worst- and best-case scenario – the latter given only a slight probability of occurring.

The uncertainty was, of course, reflected in the world’s so-called fear gauge, the CBOE VIX Index, which jumped almost 10 percentage points, leaving it a third higher than it was six months ago. Opinions are divided on whether the increase in volatility is a gift or an omen of what is to come.

The advent of Omicron confirms that Covid-19 remains public enemy number one, ahead of inflation, as indicated in Euromonitor’s survey a month ago. Their worst-case scenario, which they labelled the Covid Pessimistic 1 scenario, assigned an 18% to 28% probability of new, more infectious or vaccine-resistant variants of the virus emerging. 

To be clear, we’re not there yet. Euromonitor’s scenario is based on five waves of infections in 2021 and 2022. It is concerning that countries in Europe, and possibly South Africa, are currently in the throes of the fourth wave.

Making material decisions that could have long-term consequences based on anecdotal evidence is never advisable. But it is human nature to try and wrench back control, sometimes when there is none, as the pandemic has shown us time and again. However, all guidance is that you need to be patient and wait for more information on the new variant and how it is likely to affect us on an individual, country or global perspective. 

UBS’s advice is to await more data and retain a balanced and longer-term perspective. It points out the following:

• Opinions regarding Omicron remain tentative. These include initial comments about whether or not the vaccines will still be effective against the variant and how virulent the vaccine is likely to be.


• Vaccines can be updated quickly. All indications are that the pharmaceutical companies will be able to develop a vaccine that is effective against the new variant, should the existing variants prove not to be.


• Governments, businesses and consumers have learnt how to adapt to restrictions. This is a common refrain from commentators and analysts, which is encouraging because in all the worst-case Omicron scenarios published so far, a return to lockdowns worsens the global economic outlook considerably.